First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)
Clinical trial NCT07679061 · RECRUITING
Trial details
- NCT number
- NCT07679061
- Sponsor
- Bristol-Myers Squibb
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2026-03-05
- Primary completion
- 2028-02-29
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.